Sanjai Jalaj, MD
Ophthalmology · Morristown, NJNPI 1437545191
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $36.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$2K
- Glaukos Corporation$2K
- Alcon$1K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$797
- Dompe US, Inc.$370
- plus $2K from 18 others
What the payments were for
- Food & beverage$9,917100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 35 | $2,079 |
| Glaukos Corporation | 18 | $1,613 |
| Alcon | 30 | $1,425 |
| AbbVie(2 entities) | 59 | $1,267 |
| Bausch & Lomb Americas Inc. | 34 | $797 |
| Dompe US, Inc. | 10 | $370 |
| Oyster Point Pharma, Inc. | 13 | $355 |
| Amgen | 2 | $245 |
| Eyevance Pharmaceuticals LLC | 6 | $225 |
| Mallinckrodt Hospital Products Inc. | 6 | $219 |
| Biotissue Holdings Inc. | 10 | $207 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $191 |
| Novartis | 16 | $142 |
| Ocular Therapeutix, Inc. | 9 | $134 |
| Sun Pharmaceutical Industries Inc. | 6 | $129 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $123 |
| NEW World Medical,inc. | 2 | $98 |
| Tarsus Pharmaceuticals, Inc. | 3 | $57 |
| Omeros Corporation | 2 | $38 |
| Harrow Eye, LLC | 2 | $32 |
| Travere Therapeutics, Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$1,468
- KXL System$606
- Photrexa$454
- TRYPTYR$393
- LUMIGAN$370
- Clareon$355
- iStent inject W$255
- COMBIGAN$245
- TEPEZZA$245
- Oxervate$245
- TYRVAYA$222
- iDoseTR$212
- iDose$159
- Flarex$150
- Tecnis IOL$146
- iStent Trabecular Micro-Bypass System Model iS3$143
- SION SURGICAL INSTRUMENT$141
- AcrySof IQ PanOptix$135
- Rocklatan$125
- Rhopressa$125
How this compares
$9,917 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 94 | $44,868 |
| RestasisCyclosporine | 35 | $38,643 |
| XiidraLifitegrast | 23 | $35,660 |
| BesivanceBesifloxacin Hcl | 100 | $22,073 |
| MieboPerfluorohexyloctane/Pf | 18 | $20,917 |
| Lotemax SmLoteprednol Etabonate | 80 | $20,425 |
| ProlensaBromfenac Sodium | 46 | $16,005 |
| VyzultaLatanoprostene Bunod | 32 | $13,843 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $11,580 |
| Alphagan PBrimonidine Tartrate | 27 | $10,064 |
| Bromfenac Sodium | 43 | $9,819 |
| Prednisolone Acetate | 287 | $7,893 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $7,665 |
| Brimonidine Tartrate | 108 | $6,266 |
| Loteprednol Etabonate | 27 | $4,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,267 | $105,154182 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $797 | $70,42073 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Lotemax Sm, Prolensa, Loteprednol Etabonate | $123 | $62,746253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Morristown
- Sean LalinMorristown$9K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.